Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

NCT00380159 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus (HIV)-1 Infection

Interventions

DRUG: Elvucitabine
DRUG: Lamivudine
DRUG: Emtricitabine

Sponsor

Alexion Pharmaceuticals, Inc.

Collaborators

[object Object]